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Abstract
Background: Most patients who use insulin do not achieve optimal glycemic control and become susceptible to complica-
tions. Numerous clinical trials have shown that frequent insulin dosage titration is imperative to achieve glycemic control.
Unfortunately, implementation of such a paradigm is often impractical. We hypothesized that the Diabetes Insulin Guidance
System (DIGS) (Hygieia, Inc., Ann Arbor, MI) software, which automatically advises patients on adjustment of insulin
dosage, would provide safe and effective weekly insulin dosage adjustments.
Subjects and Methods: In a feasibility study we enrolled patients with type 1 and type 2 diabetes, treated with a variety of
insulin regimens and having suboptimal glycemic control. The 12-week intervention period followed a 4-week baseline run-
in period. During the intervention, DIGS processed patients’ glucose readings and provided insulin dosage adjustments on a
weekly basis. If approved by the study team, the adjusted insulin dosage was communicated to the patients. Insulin
formulations were not changed during the study. The primary outcome was the fraction of DIGS dosage adjustments
approved by the study team, and the secondary outcome was improved glycemic control.
Results: Forty-six patients were recruited, and eight withdrew. The DIGS software recommended 1,734 insulin dosage
adjustments, of which 1,731 (99.83%) were approved. During the run-in period the weekly average glucose was stable at
174.2 – 36.7 mg/dL (9.7 – 2.0 mmol/L). During the following 12 weeks, DIGS dosage adjustments resulted in progressive
improvement in average glucose to 163.3 – 35.1 mg/dL (9.1 – 1.9 mmol/L) (P < 0.03). Mean glycosylated hemoglobin de-
creased from 8.4 – 0.8% to 7.9 – 0.9% (P < 0.05). Concomitantly, the frequency of hypoglycemia decreased by 25.2%.
Conclusions: The DIGS software provided patients with safe and effective weekly insulin dosage adjustments. Wide-
spread implementation of DIGS may improve the outcome and reduce the cost of implementing effective insulin
therapy.
Introduction
Insulin therapy is mandatory for all patients with type 1diabetes and ultimately needed in most patients with type 2
diabetes, as endogenous insulin secretion diminishes.1 De-
spite the availability of an array of insulin formulations with
different time–action profiles and absence of an upper dosage
limitation, most insulin users do not achieve optimal glycemic
targets (e.g., glycosylated hemoglobin [HbA1c] < 7%) and are
at increased risk of developing complications.2,3
Multiple clinical trials have shown that frequent insulin
dosage titration is a key element for successful outcome. In
these somewhat artificial and laborious clinical trial condi-
tions, study teams contacted patients every few days or weeks
to titrate insulin dosage, and thus good glycemic control was
achieved and maintained.4–7 This beneficial effect only lasted
as long as periodic adjustments were made by the medical
staff, evidenced by deterioration of glycemic control within a
few months after the study ended, very likely as insulin ti-
trations became more sporadic with less health professional
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contact.7 Unfortunately, implementation of the frequent in-
sulin titration paradigm in day-to-day clinical practice has
been hindered by a lack of medical expertise, limited reim-
bursement, and time.8
The majority of insulin users are managed by primary care
physicians and not necessarily by endocrinologists or diabetes
educators specifically trained and experienced in insulin
management.9 Consequently, insulin is underprescribed and
underdosed in many cases to avoid the most feared side effect
for patients and care providers alike, namely, hypoglyce-
mia.8,10 Hypoglycemia is often referred to as the primary
barrier to obtaining optimal glycemic control in both type 1
and type 2 diabetes.11,12
The process of insulin titration is complex and governed by
two contradicting forces: the achievement of near-normal
glucose readings and the avoidance of hypoglycemia. When
glucose levels get close to normal, the frequency of hypogly-
cemia typically increases, and vice versa. Successful maneu-
vering of these two contradicting forces to realize effective
and safe glycemic control necessitates special expertise and
time, neither of which is widely available.
To address this unmet clinical need, Hygieia, Inc. (Ann
Arbor, MI) developed the Diabetes Insulin Guidance System
(DIGS), which automatically adjusts a patient’s insulin
dosage between clinic appointments.13 If successful, such a
tool could improve diabetes management without escalating
its economic burden. In this article, we report a feasibility
study in which insulin therapy of patients with suboptimally
controlled type 1 and type 2 diabetes was adjusted weekly by
the DIGS software supervised by an expert diabetes study
team. The ability to apply the DIGS in an unsupervised
manner was assessed by monitoring events in which the




This 16-week feasibility study was designed as a prospec-
tive, open-label, uncontrolled, single-arm, single-center study.
It aimed to predict the capacity of the DIGS software to pro-
vide safe and effective, unsupervised, weekly insulin dosage
adjustments.
Settings
The study was conducted at the International Diabetes
Center at Park Nicollet, Minneapolis, MN, in accordance with
all applicable guidelines for the protection of human patients
for research as outlined in 21 CFR Part 50. All patients pro-
vided informed consent before enrollment. The protocol, its
amendments, and informed consent form were reviewed and
approved by the Park Nicollet Institutional Review Board
prior to being initiated.
Participants
All patients were receiving insulin therapy prior to en-
rollment but had suboptimal metabolic control. Patients
were eligible to participate if they were 21–70 years of age
and had had a clinical diagnosis of type 1 or type 2 diabetes
for at least 1 year. Patients were excluded from the trial if
they had a body mass index of ‡ 45 kg/m2, severe impair-
ment of cardiac, hepatic, or renal functions, psychological or
cognitive impairment, more than two episodes of severe
hypoglycemia in the past year, or a history of hypoglycemia
unawareness. Eligible patients were enrolled into one of
three treatment groups: patients with suboptimally con-
trolled type 1 diabetes (HbA1c ‡ 7.4%) treated with basal-
bolus insulin therapy and incorporating carbohydrate
counting (Group I), patients with suboptimally controlled
type 2 diabetes (HbA1c ‡ 7.4%) treated with basal-bolus
insulin therapy (without carbohydrate counting) (Group II),
and patients with suboptimally controlled type 2 diabetes
(HbA1c ‡ 7.8%) treated with twice-daily biphasic insulin
(Group III). The higher threshold HbA1c in the latter group
was chosen to reinforce its statistical power, in view of the
likely inferiority of biphasic insulin therapy compared with
basal-bolus regimens.14
Intervention
During the first 4 weeks patients continued their pre-
enrollment regimens without intervention. During this period
patients were acquainted with weekly submission of a dia-
betes diary, but their insulin dosage was unaltered. During
the remaining 12 weeks, DIGS adjusted patients’ insulin
dosage on a weekly basis, based on self-measured blood
glucose readings reported on patients’ diaries (an example is
given in Fig. 1A). Upon review and approval by the study
team, the DIGS software insulin dosage recommendations
were communicated to the patients. Although generally en-
couraged to follow dosage recommendations, patients devi-
ated from the prescribed dosage during certain situations
(e.g., anticipated physical activity). Patients in Groups I and II
were asked to test and record their capillary glucose four
times a day before meals and before bedtime, and patients in
Group III were asked to test twice a day, before breakfast and
dinner. All patients were asked to measure capillary glucose
during the night every 5–9 days. Information captured in di-
aries included time-stamped scheduled and unscheduled
glucose readings, insulin doses, and carbohydrate quantities
(Group I only).
Main outcome measures
The primary study outcome was the fraction of dosage
adjustments made by DIGS and conveyed to the patients
without intervention from the study team. Events in which
the study team decided to override the software insulin dos-
age adjustments were thoroughly documented to enable full
investigation of each incident. The efficacy of the weekly ad-
justments was documented by improvement in weekly mean
of self-measured glucose. The secondary efficacy outcome
was defined as at least a 10% decrease in weekly mean blood
glucose between Weeks 4 and 16 (when insulin dosage ad-
justments were made). Additional efficacy analyses included
reduction in HbA1c and fructosamine between Weeks 4 and
16. The latter values were not used as primary efficacy end
points because of their inherent inability to assess glycemic
attenuations over a relatively short period of 12 weeks.15 The
safety of the weekly adjustments was documented by the fre-
quency of hypoglycemia. Hypoglycemia was defined as a
blood glucose level of < 65 mg/dL ( < 3.6 mmol/L), severe
hypoglycemia was defined as a hypoglycemic episode requir-
ing assistance of another person, and a severe adverse event
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was defined as an event resulting in death, life-threatening
experience, hospitalization, or significant disability.
Software description and utilization
The DIGS software incorporates algorithms that process
time-tagged glucose readings and adjust insulin dosage while
ignoring any additional parameters. The software was de-
veloped by E.B. and I.H. prior to the study. The algorithms
embedded in the software are based on guidelines for insulin
management16 and on the following four principles:
a. Time-tagged (e.g., pre-breakfast, bedtime) glucose
readings were the only input used to adjust the current
dosage and create recommendations for the next insulin
dosage.
b. Insulin dosage (for all insulin types) was increased for
glucose level above target and decreased for glucose
level below target.
c. The intensity of adjustments decreases as glucose
readings get closer to target to prevent unstable oscil-
lations of dosage.
d. The ability to detect ‘‘outliers.’’ The software utilized
higher-order statistics to detect outliers and treats them
separately from the remainder of the data.
Statistical methods
The study was designed as intention-to-treat. Because
each group was analyzed independently unrelated to other
groups, no statistical comparison was done for demographic
FIG. 1. Capillary glucose levels during the study. (A) An example of a patient managed with the Diabetes Insulin Guidance
System (DIGS) software in Group II. This was a 58-year-old woman with a 13-year history of type 2 diabetes, complicated
with neuropathy and nephropathy. (Upper panel) Insulin dosage. (Lower panel) Weekly mean glucose and events of hypo-
glycemia. During the first 4 weeks the subject continued to follow her current insulin dosage. During the active phase of the
study (Weeks 4–16), the DIGS software adjusted each component of the basal-bolus regimen. Her total daily insulin dosage
increased by 19% (from 123 to 151 units/day), but its distribution considerably changed, that is, different components in the
regimen were diametrically redirected according to glucose patterns. (B) Weekly mean glucose (and regression lines) in
Groups I and II. (C) Weekly mean glucose in Group III (because of fewer data points, a regression line was not plotted). (D)
Weekly mean glucose (and regression line) of patients with and without frequent hypoglycemia. During the active 12 weeks
weekly mean glucose improved when possible. A1C, glycosylated hemoglobin.
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and clinical characteristics. Normality was assessed by the
Shapiro–Wilk test. Attenuations in weekly mean glucose were
assessed for statistical significance by a mixed model repeated-
measurements analysis. Patients’ HbA1c and fructosamine
were compared by paired two-tailed Student’s t test or, if non-
normally distributed, by the Wilcoxon test. The frequency and
severity of hypoglycemia were compared by unpaired Stu-
dent’s t test or, if non-normally distributed, by the Mann–
Whitney test. Results are presented as mean – SD values, and a
value of P < 0.05 was defined as statistically significant.
Results
Study population
In total, 46 patients were enrolled: 38 completed, and
eight were withdrawn (Supplementary Table S1 [Supple-
mentary Data are available online at www.liebertonline
.com/dia]). Six of the eight patients were withdrawn during
the run-in period, before intervention was initiated. Of these
patients, one failed to meet the inclusion criteria, and two
patients withdrew consent during the first week of the run-
in period. One patient in Group I withdrew consent 9 weeks
after the beginning of the study in order to start a pump
therapy, and one patient from this group was withdrawn 5
weeks after the beginning of the study because he was un-
able to be consistent in carbohydrate counting techniques.
Available data from patients who withdrew from the study
were used for analysis as part of the intention-to-treat de-
sign. The entire study population was cumulatively fol-
lowed up for 12.2 patient-years. Patients’ demographics,
comorbidities, and diabetes medications are outlined in
Table 1. Mean baseline HbA1c across all three groups was
8.9 – 1.1%. (Average daily insulin dosage and basal to bolus
ratios are given in Supplementary Table S2.) As expected,
patients with type 1 diabetes required more attention from
the study team. This reinforced consistency and accuracy of
carbohydrate counting and improved adherence to re-
commended insulin dosage.
Run-in period
During the first 4-week run-in period, patients became ac-
quainted with the study protocol while continuing their pre-
enrollment insulin dosage and submitting their diaries
weekly. During this period patients measured capillary glu-
cose tests more than requested. Likely because of trends
preceding the study and the Hawthorne effect, mean HbA1c
Table 1. Baseline Demographics and Clinical Characteristics
Total (n = 46) Group I (n = 20) Group II (n = 20) Group III (n = 6)
Sex
Male 27 (59%) 13 (65%) 10 (50%) 4 (66.7%)
Female 19 (41%) 7 (35%) 10 (50%) 2 (33.3%)
Age (years) 52 (12) 44 (12) 60 (7) 55 (7)
Race
White 45 (98%) 20 (100%) 20 (100%) 5 (83%)
African American 1 (2%) — — 1 (17%)
Ethnicity
Non-Hispanic/Latino 46 (100%) 20 (100%) 20 (100%) 6 (100%)
Insulin typesa
Glargine 40 (89.9%) 20 (100%) 20 (100%) —
Lispro 22 (55%) 13 (65%) 9 (45%) —
Aspart 18 (45%) 7 (35%) 11 (55%) —
Aspart-mix70/30 5 (10.9%) — — 5 (83%)
Humulin-mix70/30 1 (2.2%) — — 1 (17%)
Other medications
Glucophage 17 (37%) — 12 (60%) 5 (83%)
Glipizide 1 (2%) — 1 (5%) —
Diabetes complications
Retinopathy 11 (24%) 6 (30%) 5 (25%) —
Nephropathy 11 (24%) 3 (15%) 4 (20%) 4 (67%)
Neuropathy 18 (39%) 4 (20%) 10 (50%) 4 (67%)
Comorbidities
Hypertension 24 (52%) 2 (10%) 17 (85%) 5 (83%)
Dyslipidemia 41 (89%) 16 (80%) 19 (95%) 6 (100%)
Coronary artery disease 6 (13%) 1 (5%) 4 (20%) 1 (17%)
Congestive heart failure 1 (2%) — 1 (5%) —
Cerebral vascular disease 1 (2%) — 1 (5%) —
Smoking (current) 4 (8.7%) 2 (10%) 2 (10%) —
BMI (kg/m2) 33 (7) 28 (5) 37 (6) 35 (4)
Duration of diabetes (years) 18 (10) 25 (11) 14 (5) 11 (3)
Baseline HbA1c (%) 8.9 (1.1) 8.9 (0.9) 8.8 (0.8) 9.0 (2.1)
Data are number (%) or mean (SD).
aGlargine (sanofi-aventis, Bridgewater, NJ), Lispro (Eli Lilly, Indianapolis, IN), Aspart (Novo-Nordisk, Princeton, NJ), Aspart-mix70/
30 (Novo-Nordisk), or Humulin-mix70/30 (NPH/regular) (Eli Lilly).
BMI, body mass index; HbA1c, glycosylated hemoglobin.
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improved by 0.5% (P < 0.0001) during the run-in period.
Glucose testing frequency was stable during the active inter-
vention phase (roughly four per day for Groups I and II and
two per day for Group III).
Study team overrides
The DIGS software recommended 1,734 insulin dosage
adjustments, of which 1,731 (99.83%) were approved by the
study team. Three nonconsecutive recommendations in dif-
ferent patients were overruled. In the first case for a Group III
patient, a software ‘‘bug’’ yielded an erroneous recommen-
dation. The study team was advised of the situation, prior to
reporting the recommendation to the patient, by the sponsor
who recognized the case. This ‘‘bug’’ was subsequently cor-
rected. In the second case for a Group I patient in Week 10, the
DIGS software recommended changing dinner insulin-to-
carbohydrate ratio from 1:2 (i.e., 1 unit of insulin for every 2 g
of carbohydrates) to 1:1. This patient consumed about 38 g of
carbohydrates at dinner, and his daily total insulin was about
80 units. The study team instead recommended a ratio of 1:1.7.
On Week 11, it was thought the patient required an additional
increase of prandial insulin dosage, and the regimen for this
patient was changed to a basal-bolus without carbohydrate
counting. In the third case for a Group I patient in Week 12,
the study team preferred to keep a patient’s breakfast insulin-
to-carbohydrate ratio at 1:3 and rejected the DIGS recom-
mendation to increase the ratio to 1:2. This patient consumed
about 40 g of carbohydrates at breakfast, and his daily total
insulin was about 105 units.
Insulin dosage titrations made by DIGS and overseen
by the study team improved glycemia
Over a cumulative 8.9 patient-years (the 12-week inter-
vention period), patients were provided with 1,734 (1,731
uninterrupted) weekly insulin dosage adjustments. These
included four recommendations per week for Groups I and II
(three mealtime boluses and one basal; a correction factor was
also used but not counted as a separate recommendation as it
is calculated based on the other four dosage recommenda-
tions) and two recommendations per week for Group III
(breakfast and dinner). Weekly mean glucose progressively
improved during the active 12 weeks across all groups.
Among patients in Group II (Fig. 1B), weekly mean glucose
improved by 5.2%, and among patients in Group III (Fig. 1C),
weekly mean glucose improved by 18.3%. Cumulatively for
all patients with type 2 diabetes (Groups II and III), weekly
mean glucose improved by 7.4%. Among patients in Group I
(patients with type 1 diabetes), whose frequency of hypo-
glycemia was significantly higher, weekly mean glucose did
not significantly improved (Fig. 1B). There was a significant
reduction over the entire study population in HbA1c and
fructosamine (Supplementary Table S2), although the efficacy
end point ( > 10% improvement in weekly mean glucose) was
not attained. Generally, patients with type 2 diabetes experi-
enced greater reduction in these parameters.
Insulin dosage titrations made by DIGS and overseen
by the study team reduced hypoglycemia
Thirty-eight of the 46 patients enrolled reported 632 epi-
sodes of minor hypoglycemia during the study. No episodes
of severe hypoglycemia were documented. As shown in
Figure 2B, during the 4-week run-in period patients reported
63.5 – 100.6 episodes of minor hypoglycemia per patient-year.
The frequency of hypoglycemia did not significantly change
during the 12-week active phase (weeks 5–16) when patients
reported 47.5 – 73.3 episodes per patient-year (P = 0.8). Yet, as
shown in Figure 2A, glucose levels falling below the hypo-
glycemic threshold (glucose < 65 mg/dL [ < 3.6 mmol/L])
during the 12-week active phase were significantly milder
than the ones reported during the 4-week run-in period
(P = 0.02).
Performance according to individual glycemic
balance (post hoc analysis)
Post hoc analysis suggests that the study population could
fit into two glycemic profiles. The hypothesis generated by
this post hoc analysis is presented herein because of its po-
tential clinical relevance and because of the authors’ intent to
validate it in another study. About one-quarter of the patients
exhibited a high frequency of hypoglycemia, which may
preclude safe reduction of average glucose and HbA1c, par-
ticularly among patients managed in primary care clinics.11
We sought to separate the study population based on their
hypoglycemic frequency. To refrain from partiality, it was
essential to identify an exogenous hypoglycemia frequency
threshold, unrelated to the study results. A frequency of 85
events of minor hypoglycemia per patient-year was chosen as
a cutoff point because it was double the frequency among
patients with type 1 diabetes found in a community-based
survey.17 It was thought that such frequency might be con-
sidered unsafe or at least excessive by primary care teams for
their insulin-treated patients. Based on this threshold, patients
were separated into two groups:
i. Patients with frequent hypoglycemia (an example is
given in Supplementary Fig. S1A). Ten of the 20 patients
enrolled with type 1 diabetes and two of the 26 patients
enrolled with type 2 diabetes demonstrated a high rate
of hypoglycemia. Ten of these patients completed the
study (eight with type 1 diabetes and two with type 2
diabetes). As shown in Figure 2C, during the 12-week
active phase reduction of hypoglycemia was achieved
by changing the distribution of insulin formulations (i.e.,
fast-acting insulin for each meal and long-acting insulin)
while maintaining stable average daily total insulin
dose. In these patients DIGS insulin dosage adjustments
resulted in an increase of mean weekly glucose by
18.7%, from 152.5 – 23.3 mg/dL (8.5 – 1.3 mmol/L) to
180.9 – 32.9 mg/dL (10 – 1.8 mmol/L) (Fig. 1D), while
the frequency of hypoglycemia significantly decreased
by 36.3% (P = 0.047), from 167.3 to 106.6 events per
patient-year (Fig. 2B). For these patients, HbA1c did not
significantly change (8.1% to 8.2%; P = 0.5).
ii. Patients without frequent hypoglycemia (an example is
given in Supplementary Fig. S1B). Ten of the 20 patients
with type 1 diabetes and 24 of the 26 with type 2 dia-
betes (18 in Group II and six in Group III) did not
demonstrate a high rate of hypoglycemia. Clearly, in
these cases it was possible to safely increase insulin
dosage. Of the 34 patients composing this category, 28
completed the study (six with type 1 diabetes and 22
with type 2 diabetes [18 in Group II and four in Group
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III]). As shown in Figure 1D, in this group weekly mean
glucose improved by 12.2%, from 178.8 – 36.0 mg/dL
(9.9 – 2 mmol/L) to 157 – 34.2 mg/dL (8.7 – 1.9 mmol/
L), meeting the study efficacy end point ( > 10% re-
duction in weekly mean glucose), while maintaining a
low and stable rate of hypoglycemia of approximately
25 events per patient-year (Fig. 2B). During the 12-week
active phase, daily total insulin dosage was increased,
and HbA1c decreased from 8.5% to 7.8% (P = 0.0005).
Overall, this post hoc analysis suggests that the DIGS soft-
ware was able to provide effective and safe insulin dosage
adjustments to improve glycemic control for all subjects, as
defined by reducing either the average glucose or hypoglyce-
mia frequency or both, by tailoring each individual’s therapy.
Discussion
This feasibility study tested the autonomy of the DIGS
software in its ability to provide safe and effective weekly
insulin dosage adjustments. This novel approach was in-
tended to facilitate frequent insulin dosage adjustments be-
tween clinic appointments to achieve and maintain improved
glycemic control. The utility of frequent insulin dosage ad-
justments has been widely demonstrated in clinical studies4–7
but has not been implemented in day-to-day clinical practice
because of insufficiency of medical expertise, limited time and
reimbursement, and fear of hypoglycemia.8 It has been pre-
viously demonstrated that glucose readings are sufficient to
adjust insulin dosage, provided that insulin adjustments are
modest and frequent.13 Moreover, because of the dynamic
nature of insulin therapy, frequent insulin dosage adjust-
ments are needed not only to achieve the therapy goal but also
to maintain it.18
During a cumulative period of 8.9 patient-years, the DIGS
software provided 1,731 effective and safe weekly insulin
dosage adjustments for patients with type 2 and type 1 dia-
betes, using a variety of insulin regimens. In only two cases
did the study team disagree with the software recommenda-
tions (excluding the software ‘‘bug’’) to increase insulin-to-
carbohydrate ratios. Consequently, the DIGS software was
changed, after the study, to refrain from recommending high
insulin-to-carbohydrate ratios.
The weekly dosage adjustments were shown to improve
glycemia, evidenced by a lower rate of hypoglycemia, re-
duced weekly mean glucose, or both (defined as improved
glycemic balance or improved glycemic composite index).
Weekly mean glucose significantly improved in patients in
Groups II and III with type 2 diabetes. It is notable that all
patients in these groups, excluding two patients, did not have
frequent hypoglycemia. Conversely, half of the patients in
FIG. 2. Hypoglycemia during the study. (A) Histogram
depicting frequency of hypoglycemic glucose readings per
glucose value during the 12-week active phase and the 4-
week run-in period. The histogram shows that glucose
readings below 65 mg/dL ( < 3.6 mmol/L) during the active
phase had different distribution than during the run-in period
and were generally milder. (B) Frequency of minor hypogly-
cemia (glucose < 65 mg/dL [ < 3.6 mmol/L]) during each
quartile for all patients and patients with or without frequent
hypoglycemia ( > 85 events per patient-year). (C) Total daily
insulin in patients with frequent minor hypoglycemia. During
the active 12-week period, the frequency and severity of hy-
poglycemia decreased.
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Group I with type 1 diabetes had frequent hypoglycemia—
nearly three times the rate reported by others among patients
with type 1 diabetes.11,17 It is surprising that these patients
were not exceptionally insulin sensitive (according to their
daily total insulin [Fig. 2C]). Thus in these patients, during the
study period the DIGS software primarily decreased the fre-
quency of hypoglycemia and did not achieve a significant
reduction in weekly mean glucose or HbA1c. The relatively
large group of patients with frequent hypoglycemia may have
been the result of the study being conducted in a referral
center focused on diabetes management and education.
Moreover, the average duration of diabetes in our study
population was fairly long compared with many clinical trials
(Table 1), and it was demonstrated that the propensity to
develop hypoglycemia in insulin-treated patients with type 2
diabetes increases several years after insulin initiation.17,19,20
In a post hoc analysis we identified two different glycemic
profiles that may prompt different approaches in insulin ti-
trations. The hypothesis generated by this post hoc analysis
suggests that during the study period each individual pa-
tient’s requirements were diverse, yet the DIGS software tai-
lored the therapy to match the unique patient’s needs.
Specifically, patients with frequent hypoglycemia were able
to reduce its frequency without substantial deterioration in
glycemic control, and patients without frequent hypoglyce-
mia had significantly improved average glucose. Accord-
ingly, the efficacy end point of reduced mean glucose could
only be safely achieved by patients having moderate or low
frequency of hypoglycemia (about three-quarters of the pa-
tients). This hypothesis will be tested in a larger clinical trial.
Hypoglycemia is the main limiting factor in obtaining op-
timal glycemic control in patients on insulin (in both type 1
and type 2 diabetes)11 and has been shown to be inversely
related to average glucose and HbA1c.7 It has been demon-
strated that the main risk factor for severe hypoglycemia is
previous hypoglycemic events.11,17 Because in day-to-day life
hypoglycemic events are often reviewed in a retrospective
manner, during infrequent clinic appointments, it is not sur-
prising they are hard to prevent. As we demonstrated, routine
insulin dosage adjustments between appointments can re-
duce the frequency and severity of hypoglycemia and thus
enable optimization of average glucose. The incidence of mi-
nor hypoglycemia in community-based circumstances has not
been often studied, and no consensus regarding what con-
stitutes an acceptable amount of hypoglycemia20 has been
established. We elected to use 85 events per patient-year as a
threshold in our sorting process based on a large community-
based study.17 This number was independent of our study
results, and using a lower threshold would have yielded a
more significant difference between groups. Over time, with
more sophisticated technology like continuous glucose mon-
itoring21,22 included in clinical practice, it may be possible to
more accurately sort out the usual rates of mild, moderate,
and severe hypoglycemia and to determine a more precise
composite index or balance of improved glucose control
(HbA1c or average glucose) and rate of hypoglycemia.
The study was limited by lack of a control group. Thus, we
could not have unequivocally excluded the possibility that
improved glycemia resulted from participation in the study.
During the run-in period HbA1c improved, likely because of
trends preceding the study and the Hawthorne effect, evi-
denced by transient increase in glucose readings during this
period. The study duration was relatively short; therefore it is
possible that different HbA1c levels would have been re-
corded during a longer follow-up. Because weekly mean
glucose levels were stable during the run-in period and im-
proved particularly toward the middle of the active phase, it is
our belief that HbA1c would have further improved.
The DIGS concept relies on its capability to properly assist
healthcare providers in the process of insulin management
between appointments without the healthcare provider’s
constant involvement. Essentially, this is a virtual extension of
the physician’s availability to follow patients and provides
simple and safe instructions to modify treatment without in-
creased effort. We believe, that if our findings are confirmed in
a randomized controlled trial, then implementation of such a
solution on a large scale can potentially improve outcomes of
insulin therapy, reduce costs, and increase consistency. Ulti-
mately it may make insulin therapy more suitable for the
majority of people with type 2 diabetes (most are treated in
primary care clinics) who fail to successfully control glucose
level with other medications. Because the fear of hypoglyce-
mia is one of the main limitations in insulin therapy, it was
important to show that the DIGS software does not increase
its rate.
A clinical implementation of DIGS is planned to be tested in
a prospective, multicenter, randomized controlled study.
Additional studies are also needed to focus on improved
glycemic balance among the minority of patients who expe-
rience frequent hypoglycemia. The DIGS software may serve
as a bridge from the currently ineffective standard practice of
sparse evaluation of glucose patterns and insulin dosage ad-
justments to the desired and steadily evolving closed loop or
artificial pancreas technology.23–25
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